Clinical Trial

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Study acronym: KRYSTAL-12
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
Protocol Amendment History 2 changes
notable Trial sites expanded: 343 -> 380 locations 2026-08-12
minor Completion pushed: 2026-07-02 -> 2026-10-30 2026-08-12
Trial Details
NCT Number NCT04685135
Lead Sponsor Mirati Therapeutics Inc.
Conditions Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Enrollment 453 participants
Start Date 2021-02-23
Primary Completion 2023-12-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-11